



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07B 61/00	A2	(11) International Publication Number: WO 00/20357 (43) International Publication Date: 13 April 2000 (13.04.00)
<p>(21) International Application Number: PCT/GB99/03286</p> <p>(22) International Filing Date: 5 October 1999 (05.10.99)</p> <p>(30) Priority Data: 9821655.9 5 October 1998 (05.10.98) GB</p> <p>(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): <u>CARR, Robin, Arthur, Ellis</u> [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). <u>GEHANNE, Sylvie</u> [FR/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming, 2, I-37100 Verona (IT). <u>KAY, Corinne</u> [FR/GB]; Glaxo Wellcome Chemistry Laboratory, University Chemistry Laboratories, The University of Cambridge, Lensfield Road, Cambridge CB2 1EW (GB). <u>McKEOWN, Stephen, Carl</u> [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). <u>MURRAY, Peter, John</u> [GB/GB]; OSI Pharmaceuticals, Aston Molecules Limited, 10 Holt Court South, Aston Science Park, Birmingham B7 4EJ (GB). <u>PAIO, Alfredo</u> [IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming, 2, I-37100 Verona (IT). <u>SCI-</u></p>		<p><u>CINSKI, Jan, Josef</u> [GB/GB]; Glaxo Wellcome Chemistry Laboratory, University Chemistry Laboratories, The University of Cambridge, Lensfield Road, Cambridge CB2 1EW (GB). <u>WATSON, Stephen, Paul</u> [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). <u>WILLIAMS, Geoffrey, Martyn</u> [NZ/GB]; Glaxo Wellcome Chemistry Laboratory, The University of Cambridge, Lensfield Road, Cambridge CB2 1EW (GB). <u>ZARAMELLA, Alessio</u> [IT/IT]; Glaxo Wellcome SpA, Via Alessandro Fleming, 2, I-37100 Verona (IT).</p> <p>(74) Agent: QUILLIN, Helen, K.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
(54) Title: CHEMICAL CONSTRUCTS		
<p>(57) Abstract</p> <p>The invention provides a chemical construct for use in solid phase synthesis comprising a solid support Q having linked thereto via a connecting group Y a substrate R; the connecting group Y having first and second cleavage sites which are orthogonally and selectively cleavable; the second cleavage site being selectively cleavable to release the substrate; and the first cleavage site being located at a position between the second cleavage site and the solid support and being selectively cleavable to release a fragment Fr comprising the substrate and at least a portion of the connecting group Y; characterised in that cleavage at the first cleavage site forms or introduces on the chemical fragment Fr at the first cleavage site a moiety comprising a sensitising group G (such as an amino group) which sensitises the chemical fragment Fr to instrumental, e.g. mass spectroscopic, analysis. Also provided are methods of analysis employing the constructs, as well as intermediate constructs.</p>		